Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Consensus guidelines on the neurologist's role in the management of neurogenic lower urinary tract dysfunction in multiple sclerosis.
De Ridder D, Van Der Aa F, Debruyne J, D'hooghe MB, Dubois B, Guillaume D, Heerings M, Ilsbroukx S, Medaer R, Nagels G, Seeldrayers P, Van Landegem W, Willekens B, Zicot AF. De Ridder D, et al. Among authors: medaer r. Clin Neurol Neurosurg. 2013 Oct;115(10):2033-40. doi: 10.1016/j.clineuro.2013.06.018. Epub 2013 Jul 20. Clin Neurol Neurosurg. 2013. PMID: 23880016
Risks of multiple sclerosis in relatives of patients in Flanders, Belgium.
Carton H, Vlietinck R, Debruyne J, De Keyser J, D'Hooghe MB, Loos R, Medaer R, Truyen L, Yee IM, Sadovnick AD. Carton H, et al. Among authors: medaer r. J Neurol Neurosurg Psychiatry. 1997 Apr;62(4):329-33. doi: 10.1136/jnnp.62.4.329. J Neurol Neurosurg Psychiatry. 1997. PMID: 9120443 Free PMC article.
Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program.
van Pesch V, Bartholomé E, Bissay V, Bouquiaux O, Bureau M, Caekebeke J, Debruyne J, Declercq I, Decoo D, Denayer P, De Smet E, D'hooghe M, Dubois B, Dupuis M, Sankari SE, Geens K, Guillaume D, van Landegem W, Lysandropoulos A, de Noordhout AM, Medaer R, Melin A, Peeters K, Ba RP, Retif C, Seeldrayers P, Symons A, Urbain E, Vanderdonckt P, Van Ingelghem E, Vanopdenbosch L, Vanroose E, Van Wijmeersch B, Willekens B, Willems C, Sindic C. van Pesch V, et al. Among authors: medaer r. Acta Neurol Belg. 2014 Sep;114(3):167-78. doi: 10.1007/s13760-014-0308-9. Epub 2014 Jun 11. Acta Neurol Belg. 2014. PMID: 24915752
Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon beta in relapsing- remitting Multiple Sclerosis (ASIIMS) trial.
Gonsette RE, Sindic C, D'hooghe MB, De Deyn PP, Medaer R, Michotte A, Seeldrayers P, Guillaume D; ASIIMS study group. Gonsette RE, et al. Among authors: medaer r. Mult Scler. 2010 Apr;16(4):455-62. doi: 10.1177/1352458509360547. Epub 2010 Mar 3. Mult Scler. 2010. PMID: 20200198 Clinical Trial.
Long-term follow up of glatiramer acetate compassionate use in Belgium.
Sindic CJ, Seeldrayers P, Vande Gaer L, De Smet E, Nagels G, De Deyn PP, Medaer R, Guillaume D, D'Hooghe MB, Deville MC, Decoo D, Sadzot B, Van Landegem W, Strauven T, Pepin J, Merckx H, Caekebeke J, van der Tool MA. Sindic CJ, et al. Among authors: medaer r. Acta Neurol Belg. 2005 Jun;105(2):81-5. Acta Neurol Belg. 2005. PMID: 16076061 Clinical Trial.
The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing-remitting multiple sclerosis.
De Stefano N, Filippi M, Confavreux C, Vermersch P, Simu M, Sindic C, Hupperts R, Bajenaru O, Edan G, Grimaldi L, Marginean I, Medaer R, Orefice G, Pascu I, Pelletier J, Sanders E, Scarpini E, Mancardi GL. De Stefano N, et al. Among authors: medaer r. Mult Scler. 2009 Feb;15(2):238-43. doi: 10.1177/1352458508098269. Epub 2008 Nov 5. Mult Scler. 2009. PMID: 18987103 Free article. Clinical Trial.
41 results